SCHEMBL22326308

SCHEMBL22326308

CC(C)(C)OC(=O)COCCOCCOCCOCCOCCOCCOCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.51
PPARA Q07869 2/20 0.48
NAAA Q02083 1/20 0.44
PPARG P37231 1/20 0.43
CTSS P25774 1/20 0.43
TSHR P16473 1/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.40
MAPK1 P28482 1/20 0.40
SYK P43405 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA7 P43166 1/20 0.40
CA14 Q9ULX7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20534920 1.00 L3MBTL1 (0.51) L3MBTL1PPARANAAAPPARGCTSS
SCHEMBL15884132 1.00 L3MBTL1 (0.51) L3MBTL1PPARANAAAPPARGCTSS
SCHEMBL26813320 1.00 L3MBTL1 (0.51) L3MBTL1PPARANAAAPPARGCTSS
SCHEMBL16346595 1.00 L3MBTL1 (0.51) L3MBTL1PPARANAAAPPARGCTSS
SCHEMBL25533030 1.00 L3MBTL1 (0.51) L3MBTL1PPARANAAAPPARGCTSS
SCHEMBL16346406 0.98 L3MBTL1 (0.52) L3MBTL1PPARANAAAPPARGCTSS
SCHEMBL18530395 0.96 L3MBTL1 (0.54) L3MBTL1PPARANAAAPPARGCTSS
SCHEMBL16346501 0.96 L3MBTL1 (0.54) L3MBTL1PPARANAAAPPARGCTSS
SCHEMBL26116555 0.96 L3MBTL1 (0.54) L3MBTL1PPARANAAAPPARGCTSS
SCHEMBL17940957 0.96 L3MBTL1 (0.54) L3MBTL1PPARANAAAPPARGCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220105188-A1 TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-04-07 US disclosed
EP-3922632-A1 TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT Korea Research Institute of Chemical Technology (KR) 2021-12-15 EP disclosed
WO-2020162725-A1 TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT 한국화학연구원 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220105188-A1 TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT EED, VHL, CUL1 L3MBTL1 3035/4885PPARA 3868/4885NAAA 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.